# Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

> **NCT04323202** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Basal Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **OTHER:** Tissue collection

## Key facts

- **NCT ID:** NCT04323202
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2024-07-23
- **Final completion:** 2025-06-25
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323202, "Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT04323202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*